Symbols

FDMT

4D Molecular·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 3

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Gap Up

Significant Revenue Decline

High Cash/net Profit Ratio

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FDMT

4d Molecular Therapeutics, Inc.

A clinical-stage biotherapeutics company that develops therapies for genetic diseases

Industry

Biological Technology

Established Date

03/11/2015

Listing Date

12/11/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

196

Fiscal Year Ends

12-31

Website

www.4dmoleculartherapeutics.com

Security Type

Common stock

Office address

5858 Horton Street #455, Emeryville, CA 94608

Business

Introduction

4D Molecular Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 11, 2015. The company is a late-stage biotechnology company focused on the development of durable, disease-targeting therapies, and its adeno-associated virus (AAV) vectors are developed using its proprietary Therapeutic Vector Evolution (TVE) platform. The TVE platform uses the principle of directed evolution to generate and screen AAV vectors in non-human primate models that have properties designed to overcome the limitations of traditional AAV and can target disease-related tissues with high unmet need through conventional and local administration routes. 4D's clinical research is mainly focused on vectors developed using the TVE platform for the treatment of retinal and pulmonary disease candidates.

Company Financials

EPS

FDMT has released its 2025 Q4 earnings. EPS was reported at 0.43, versus the expected -0.53, beating expectations. The chart below visualizes how FDMT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

FDMT has released its 2025 Q4 earnings report, with revenue of 85.09M, reflecting a YoY change of 8508900.00%, and net profit of 19.40M, showing a YoY change of 139.05%. The Sankey diagram below clearly presents FDMT's revenue sources and cost distribution.